CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
A092105 Alliance Randomized Phase 2 Study of Nivolumab and Ipilimumab with or without Cabozantinib in Patients with Advanced Nasopharyngeal Carcinoma that have Progressed after Platinum Treatment and Immunotherapy Adult CIRB - Late Phase Emphasis
A092107 Alliance A Randomized Phase 2 Trial with a Safety Lead-In to Evaluate Palbociclib versus Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated Liposarcoma Adult CIRB - Late Phase Emphasis
A092204 Alliance A Phase II Study of Cabozantinib in Combination with Cemiplimab (REGN2810) (Cabo-Cemiplimab (REGN2810)) versus Cabozantinib Alone in Adolescents and Adults with Advanced Adrenocortical Cancer Adult CIRB - Late Phase Emphasis
A092205 Alliance Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Platinum Refractory Disease Adult CIRB - Late Phase Emphasis
A151216 Alliance Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) Adult CIRB - Late Phase Emphasis
A151804 Alliance Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events Adult CIRB - Late Phase Emphasis
A171601 Alliance A phase II trial assessing the tolerability of palbociclib in combination with letrozole or fulvestrant in patients aged 70 and older with estrogen receptor-positive, HER2-negative metastatic breast cancer Cancer Prevention and Control CIRB
A171901 Alliance Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated with First-Line MK-3475 (Pembrolizumab) +/- Chemotherapy (Oncologist's/Patient's Choice) Cancer Prevention and Control CIRB
A191402CD Alliance Testing Decision Aids to Improve Prostate Cancer Decisions for Minority Men Cancer Prevention and Control CIRB
A191901 Alliance Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions Cancer Prevention and Control CIRB